Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Xeris Biopharma Holdings (XERS) Invested Capital (2020 - 2025)

Historic Invested Capital for Xeris Biopharma Holdings (XERS) over the last 6 years, with Q3 2025 value amounting to $218.6 million.

  • Xeris Biopharma Holdings' Invested Capital rose 1634.03% to $218.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $218.6 million, marking a year-over-year increase of 1634.03%. This contributed to the annual value of $202.5 million for FY2024, which is 996.09% up from last year.
  • Latest data reveals that Xeris Biopharma Holdings reported Invested Capital of $218.6 million as of Q3 2025, which was up 1634.03% from $199.3 million recorded in Q2 2025.
  • Xeris Biopharma Holdings' Invested Capital's 5-year high stood at $234.1 million during Q1 2022, with a 5-year trough of $85.3 million in Q3 2021.
  • Moreover, its 5-year median value for Invested Capital was $201.8 million (2023), whereas its average is $198.4 million.
  • As far as peak fluctuations go, Xeris Biopharma Holdings' Invested Capital soared by 49467.08% in 2021, and later plummeted by 2071.45% in 2023.
  • Over the past 5 years, Xeris Biopharma Holdings' Invested Capital (Quarter) stood at $183.3 million in 2021, then grew by 26.71% to $232.3 million in 2022, then fell by 20.71% to $184.2 million in 2023, then rose by 9.96% to $202.5 million in 2024, then increased by 7.96% to $218.6 million in 2025.
  • Its Invested Capital stands at $218.6 million for Q3 2025, versus $199.3 million for Q2 2025 and $194.6 million for Q1 2025.